EX-10.1
from 10-Q
8 pages
This Waiver (This “Waiver”), Dated as of July 14, 2022, Is Entered Into by and Among Biocryst Pharmaceuticals, Inc., a Delaware Corporation (The “Borrower”), the Guarantors Listed on the Signature Pages Hereto (The “Guarantors”), the Lenders Listed on the Signature Pages Hereto (Such Lenders, and the Other Lenders Party to the Credit Agreement (As Defined Below), Together With Their Respective Successors and Permitted Assigns, Each Individually, a “Lender”, and Collectively, the “Lenders”) and Athyrium Opportunities III Co-Invest 1 LP, a Delaware Limited Partnership, as Administrative Agent for the Lenders (In Such Capacity, Together With Its Successors and Assigns in Such Capacity, the “Administrative Agent”), and in Light of the Following
12/34/56
EX-10.92
from 10-K
135 pages
Certain Information Has Been Omitted From This Exhibit in Places Marked “[***]” Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed or Because It Contains Personally Identifiable Information Omitted From This Exhibit Pursuant to Item 601(a)(6) Under Regulation S-K. Credit Agreement Dated as of December 7, 2020 Among Biocryst Pharmaceuticals, Inc., as the Borrower, Biocryst Ireland Limited as a Guarantor the Other Guarantors From Time to Time Party Hereto, the Lenders From Time to Time Party Hereto and Athyrium Opportunities III Co-Invest 1 LP, as Administrative Agent
12/34/56